Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Departure of Directors or Certain Officers
9 Apr 24
8-K
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
5 Apr 24
8-K
Departure of Directors or Certain Officers
2 Apr 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
14 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update
9 Nov 23
8-K
Departure of Directors or Certain Officers
1 Sep 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
8-K
Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results
2 Aug 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 Jul 23
8-K
Departure of Directors or Certain Officers
13 Jun 23
DEFA14A
Additional proxy soliciting materials
1 Jun 23
8-K
Regulation FD Disclosure
9 May 23
10-Q
2023 Q1
Quarterly report
3 May 23
8-K
Adaptive Biotechnologies Reports First Quarter 2023 Financial Results
3 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
8-K
Departure of Directors or Certain Officers
11 Apr 23
S-8
Registration of securities for employees
14 Feb 23
10-K
2022 FY
Annual report
14 Feb 23
8-K
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results
14 Feb 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results
3 Nov 22
8-K
Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million
12 Sep 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
8-K
Adaptive Biotechnologies Reports Second Quarter 2022 Financial Results
3 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 22
10-Q
2022 Q1
Quarterly report
4 May 22
8-K
Adaptive Biotechnologies Reports First Quarter 2022 Financial Results
4 May 22
DEFA14A
Additional proxy soliciting materials
22 Apr 22
DEF 14A
Definitive proxy
22 Apr 22
8-K
Other Events
25 Mar 22
8-K
Departure of Directors or Certain Officers
11 Mar 22
10-K
2021 FY
Annual report
15 Feb 22
8-K
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results
15 Feb 22
Latest ownership filings
4
PETER M NEUPERT
13 Mar 24
4
Michael J Pellini
6 Mar 24
4
KATEY EINTERZ OWEN
6 Mar 24
4
PETER M NEUPERT
6 Mar 24
4
ROBERT HERSHBERG
6 Mar 24
4
MICHELLE RENEE GRIFFIN
6 Mar 24
4
KYLE PISKEL
6 Mar 24
4
Stacy L Taylor
6 Mar 24
4
FRANCIS LO
6 Mar 24
4
SHARON BENZENO
6 Mar 24
4
JULIE RUBINSTEIN
6 Mar 24
4
HARLAN S ROBINS
6 Mar 24
4
TYCHO PETERSON
6 Mar 24
4
CHAD M ROBINS
6 Mar 24
4
SUSAN BOBULSKY
6 Mar 24
3
SUSAN BOBULSKY
6 Mar 24
SC 13G/A
VIKING GLOBAL INVESTORS LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
ARK Investment Management LLC
29 Jan 24
SC 13G
BlackRock Inc.
26 Jan 24
4
PETER M NEUPERT
15 Dec 23
4
KYLE PISKEL
20 Nov 23
144
Notice of proposed sale of securities
8 Aug 23
4
NITIN SOOD
8 Aug 23
4
TYCHO PETERSON
21 Jun 23
4
TYCHO PETERSON
20 Jun 23
144
Notice of proposed sale of securities
20 Jun 23
144
Notice of proposed sale of securities
15 Jun 23
4
TYCHO PETERSON
6 Jun 23
4
R MARK ADAMS
12 Apr 23
4
MICHELLE RENEE GRIFFIN
29 Mar 23
4
Michael J Pellini
8 Mar 23
4
KATEY EINTERZ OWEN
8 Mar 23
4
PETER M NEUPERT
8 Mar 23
4
ROBERT HERSHBERG
8 Mar 23
4
MICHELLE RENEE GRIFFIN
8 Mar 23
4
Kevin T Conroy
8 Mar 23
4
Leslie Trigg
8 Mar 23
4
KYLE PISKEL
8 Mar 23
4
FRANCIS LO
8 Mar 23